Study Finds 1 in 3 Americans Without Heart Disease Miss New Cholesterol Goals—and 3 in 4 Go Untreated | Mass General Brigham
Skip to cookie consent<br>Skip to main content<br>Skip to pause video preview<br>Skip to alerts<br>Skip to pause carousel
Featured Links
Giving to Mass General Brigham
Featured Links
Giving to Mass General Brigham
Featured Links
Giving to Mass General Brigham
Featured Links
Giving to Mass General Brigham
Search the Site
Site-wide search
0 items available in list
reset search
Search
Close Search
Open Menu
Site-wide search
0 items available in list
reset search
Search
Language selector navigation menu.
Giving to Mass General Brigham
Giving to Mass General Brigham
Giving to Mass General Brigham
Giving to Mass General Brigham
More alert details
Study Finds 1 in 3 Americans Without Heart Disease Miss New Cholesterol Goals—and 3 in 4 Go Untreated
Jul 20, 2026
7 minute read
Heart Conditions & Heart Surgery
Research
share on facebook
share on linkedIn
share on X, formerly known as Twitter
share by email
print article
A Mass General Brigham analysis applying the newly released 2026 U.S. cholesterol guidelines to a national sample reveals wide gaps in cholesterol control and treatment.\r\n\r\n\r\nA new study by investigators from Mass General Brigham finds that nearly 1 in 3 U.S. adults without heart disease — and almost 4 in 5 of those who have already had a heart attack, stroke or other cardiovascular event — have LDL, or “bad” cholesterol levels, above the goals set by the newly released 2026 American cholesterol guidelines. Additionally, among adults without heart disease who were above target, about 3 in 4 of those individuals are not receiving any cholesterol-lowering medication. The results are published in JAMA.\r\n“The gap between where the country’s cholesterol levels actually are and where the new guidelines say they should be is much wider than most people realize,” said lead author Shady Abohashem, MD, MPH, Head of Cardiac PET/CT Imaging Trials in the Cardiovascular Imaging Research Center with Mass General Brigham Heart and Vascular Institute. “Heart disease remains a leading cause of death in this country, and a large share of heart attacks and strokes are preventable with medications we’ve had for decades. Yet many people who could benefit from treatment aren't getting any. That is a missed opportunity at the scale of millions.”\r\nThe 2026 ACC/AHA dyslipidemia guideline introduced a new cardiovascular risk calculator and lowered LDL treatment goals, reflecting evidence that has made increasingly clear that 'lower is better' for higher-risk patients. To assess how the current U.S. population measures up against these updated treatment goals, Abohashem and his colleagues analyzed national data from approximately 2,300 adults aged 30 to 79 years in the National Health and Nutrition Examination Survey (NHANES) 2021–2023, a federally administered survey representative of roughly 178 million U.S. adults.\r\nUnder the updated guidelines, the recommended LDL level in the blood varies according to a person's cardiovascular risk: the higher a person’s overall risk, the lower their LDL should be. For instance, for adults at low risk, an LDL of 160 mg/dL or higher is the level at which the guidelines suggest considering treatment; for those with established heart disease and very high risk of future cardiovascular events, the target is below 55 mg/dL.\r\nThe researchers found substantial gaps between the new LDL goals and actual LDL levels in the population. About one-third of U.S. adults without a history of heart attack, stroke, or other cardiovascular events (primary prevention group) had LDL levels above the new recommended goals; among those, about 76% were not receiving any cholesterol-lowering medication. The gap widened sharply as risk rose: among those at the highest cardiovascular risk, about 83% were above goal, and roughly half of them were not receiving any cholesterol-lowering medication.\r\nThe gap looked different among adults with established heart disease (secondary prevention group). Nearly 4 of 5 were above the recommended goal, but most (roughly 62%) were already receiving cholesterol-lowering therapy without reaching the lower targets, pointing to a need for stronger treatment rather than starting a new one. The remaining 38% were receiving no treatment at all.\r\n"The good news is we know exactly what works, and the evidence behind these therapies is among the strongest in medicine," Abohashem said. “But these are really two different problems requiring two different solutions. In people without heart disease, most who are above target aren’t on any cholesterol-lowering medication at all, so the first step is simply starting treatment. Whereas in people who have already had a heart attack or stroke, most are already on a statin but still aren’t reaching the goal. For them, the answer isn’t starting...